Cirrhosis of the liver
Conditions
Interventions
Intervention group:Rifaximin (standard dose 200mg/ time, three times a day, for 14 days) + conservative treatment according to the condition
Control group:Conservative treatment according to the condition
Sponsors
The Affiliated Hospital of Qingdao University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-65, regardless of gender; 2. Patients with cirrhosis and PVT of cirrhosis; 3. As determined by the investigator, the subject is able to understand all relevant aspects of the study Content and comply with the requirements of the research protocol. The subject understands and signs informed consent prior to the start of the study process; 4. From signing the informed consent to the end of the study, agree to take effective contraceptive measures.
Exclusion criteria
Exclusion criteria: 1. Used antibiotics 4 weeks before treatment; 2. Primary liver cancer or other systemic tumors; 3. Liver function Child C; 4. The subject has any unstable or uncontrolled cardiovascular, pulmonary, liver, kidney, urogenital, hematological, coagulation, immunological, metabolic or other medical condition that the investigator believes would interfere with the study results or jeopardize the subject's safety; 5. The subject has a history of severe allergies; 6. Pregnant or lactating patients or patients with family planning in recent 3 months; 7. The subject has a history of substance abuse (defined as the use of any illicit drug) or alcohol abuse within 1 year prior to screening; 8. The subjects had active psychosis, which the researchers thought might interfere with their compliance with the study procedure; 9. Subject is unable to attend all study visits or follow study procedures; 10. Participated or is participating in other clinical studies within 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rifaximin reduces the incidence of PVT in high-risk patients with cirrhosis; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood routine, endotoxin, NETs markers, liver function, blood coagulation routine and other laboratory indicators;Imaging examination for PVT; | — |
Countries
China
Contacts
Public ContactXue Jing
The Affiliated Hospital of Qingdao University
Outcome results
None listed